Polymorphism in the 5′-End of the Aldose Reductase Gene Is Strongly Associated With the Development of Diabetic Nephropathy in Type I Diabetes

Recent studies suggest that the gene encoding aldose reductase (ALR2), the enzyme that converts glucose to sorbitol, may confer susceptibility to microvascular disease. DNA from 275 British Caucasian patients with type I diabetes and 102 normal healthy control patients were typed for a (CA)n dinucleotide repeat polymorphic marker in the 5′-region of the ALR2 gene using polymorase chain reaction (PGR). A highly significant decrease in the frequency of the Z+2 allele was found in patients with nephropathy (nephropathy group) compared with those with no complications after a 20-year duration of diabetes (uncomplicated group) (12.7 vs. 38.2%, respectively, Χ2 = 18.6, P < 0.00001); this was accompanied by an increase in the Z–2 allele in the nephropathy group (32.0 vs. 12.7% in the uncomplicated group). The nephropathy group also had a significant decrease in the Z/Z+2 genotype compared with the uncomplicated patients (10.7 vs. 44.7%, Χ2 = 16.0, P < 0.0001) and an increased frequency of the Z/Z-2 genotype. There was no significant association with diabetic retinopathy. These results demonstrate that the ALR2 gene may play a role in susceptibility to diabetic nephropathy; individuals with the Z+2 allele are more than seven times less likely to develop diabetic renal disease than those without this marker. This marker may prove valuable in screening for patients with diabetic nephropathy at diagnosis of diabetes.

[1]  N. Hotta,et al.  [Risk factors for the development of diabetic complications]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[2]  M. Hibberd,et al.  Chromosome 7q35 and susceptibility to diabetic microvascular complications. , 1996, Journal of diabetes and its complications.

[3]  A. Barnett,et al.  Nephropathy in Type 1 Diabetes: the Role of Genetic Factors , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[4]  K. Lam,et al.  An (A-C)n Dinucleotide Repeat Polymorphic Marker at the 5′ End of the Aldose Reductase Gene Is Associated With Early-Onset Diabetic Retinopathy in NIDDM Patients , 1995, Diabetes.

[5]  K. Lam,et al.  An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. , 1995, Diabetes.

[6]  E. Boel,et al.  Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise? , 1995, Journal of diabetes and its complications.

[7]  B. Martin,et al.  Cloning, genomic organization, and osmotic response of the aldose reductase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Cotter,et al.  The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. , 1994, Diabetes/metabolism reviews.

[9]  R. Frank The Aldose Reductase Controversy , 1994, Diabetes.

[10]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[11]  T. Mohandas,et al.  Mapping of aldose reductase gene sequences to human chromosomes 1, 3, 7, 9, 11, and 13. , 1993, Genomics.

[12]  K. Bohren,et al.  Characterization of the human aldose reductase gene promoter. , 1993, The Journal of biological chemistry.

[13]  P. Tesauro,et al.  Effect of Aldose Reductase Inhibitor (Tolrestat) on Urinary Albumin Excretion Rate and Glomerular Filtration Rate in IDDM Subjects With Nephropathy , 1993, Diabetes Care.

[14]  P. Raskin,et al.  Association of Erythrocyte Aldose Reductase Activity with Diabetic Complications in Type 1 Diabetes Mellitus , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[15]  M. Mcdaniel,et al.  Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction , 1992, Diabetes.

[16]  P. Raskin,et al.  Crucial Role of Aldose Reductase Activity and Plasma Glucose Level in Sorbitol Accumulation in Erythrocytes From Diabetic Patients , 1991, Diabetes.

[17]  J. Christiansen,et al.  Reduction of Glomerular Hyperfiltration in Normoalbuminuric IDDM Patients by 6 mo of Aldose Reductase Inhibition , 1991, Diabetes.

[18]  A. Markham,et al.  Structure of the human aldose reductase gene. , 1991, The Journal of biological chemistry.

[19]  J. Baynes Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[20]  T. Akera,et al.  Cloning and expression of human aldose reductase. , 1990, The Journal of biological chemistry.

[21]  P. Hoffman,et al.  Prolonged Aldose Reductase Inhibition in Chronic Peripheral Diabetic Neuropathy: Effects on Microangiopathy , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[22]  S. Chung,et al.  Cloning and sequence determination of human placental aldose reductase gene. , 1989, The Journal of biological chemistry.

[23]  E. Standl,et al.  Prevention and Treatment of Diabetic Late Complications , 1989 .

[24]  B. Wermuth,et al.  The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. , 1989, The Journal of biological chemistry.

[25]  C. Nishimura,et al.  Depletion of myo‐Inositol and Amino Acids in Galactosemic Neuropathy , 1987, Journal of neurochemistry.

[26]  M. Cohen Aldose reductase, glomerular metabolism, and diabetic nephropathy. , 1986, Metabolism: clinical and experimental.

[27]  J. Kinoshita,et al.  Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. , 1983, Science.

[28]  Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance , 1979, Diabetes.

[29]  A. Tjon-A-Tsien,et al.  The Efficacy of Aldose Reductase Inhibitors in the Management of Diabetic Complications , 1995 .

[30]  H Keen,et al.  The Diabetes Control and Complications Trial (DCCT). , 1994, Health trends.

[31]  A. Demaine,et al.  Polymorphisms of the aldose reductase locus (ALR2) and susceptibility to diabetic microvascular complications. , 1993, Advances in Experimental Medicine and Biology.

[32]  A. Krolewski,et al.  Epidemiology and clinical impact of diabetic late complications in IDDM , 1989 .

[33]  M. Sciadini,et al.  Reversal of proteinuria by sorbinil, an aldose reductase inhibitor in spontaneously diabetic (BB) rats. , 1988, Pharmacology.

[34]  P. Terasaki,et al.  The Data and Statistical Analysis , 1985 .